This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2011 Dec;14(8):965-6.

doi: 10.1016/j.jval.2011.10.002.

Assuring the patient centeredness of patient-reported outcomes: content validity in medical product development and comparative effectiveness research

Ethan Basch, Amy P Abernethy, Bryce B Reeve

PMID: 22152164
PMCID: PMC4319699
DOI: 10.1016/j.jval.2011.10.002

Editorial

Assuring the patient centeredness of patient-reported outcomes: content validity in medical product development and comparative effectiveness research

Ethan Basch et al. Value Health. 2011 Dec.

. 2011 Dec;14(8):965-6.

doi: 10.1016/j.jval.2011.10.002.

Authors

Ethan Basch, Amy P Abernethy, Bryce B Reeve

PMID: 22152164
PMCID: PMC4319699
DOI: 10.1016/j.jval.2011.10.002

No abstract available

PubMed Disclaimer

Comment on

Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument.
Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L. Patrick DL, et al. Value Health. 2011 Dec;14(8):967-77. doi: 10.1016/j.jval.2011.06.014. Epub 2011 Oct 13. Value Health. 2011. PMID: 22152165
Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2--assessing respondent understanding.
Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L. Patrick DL, et al. Value Health. 2011 Dec;14(8):978-88. doi: 10.1016/j.jval.2011.06.013. Epub 2011 Oct 10. Value Health. 2011. PMID: 22152166

References

1. Graham C, Bond S, Gerkovich M, Cook M. Use of the McGill Pain Questionnaire in the assessment of cancer pain: replicability and consistency. Pain. 1980;8:377–87. - PubMed
1. U.S. Food and Drug Administration. [Accessed March 20, 2011];Novantrone Drug Label. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031l....
1. FDA Office of Oncology Drug Products, Center for Drug Evaluation and Research. FDA Expectations for Endpoint Adequacy. [Accessed Octomber 3, 2011];Presentation at Oncology Drugs Advisory Committee (ODAC) 2007 Jul 24; Available from: www.fda.gov/ohrms/dockets/ac/07/slides/2007-4309s1-14-FDA-Basch.ppt.
1. U.S. Food and Drug Administration. [Accessed September 28, 2011];Guidance for industry: Patient-reported outcomes measures: Use in medical product development to support labeling claims. Issued December 2009. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati....
1. Atkinson TM, Mendoza TR, Sit L, et al. The Brief Pain Inventory and its “pain at its worst in the last 24 hours” item: clinical trial endpoint considerations. Pain Med. 2010;11:337–46. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

K07 CA124851/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources